Effect of citrate on malignant pleural mesothelioma cells: A synergistic effect with cisplatin

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 1249-1254

  Zhang, Xiaodong ^a,d   Varin, Emilie ^a   Allouche, Stéphane ^b   Yunfei, Lu ^e   Poulain, Laurent ^a   Icard, Philippe ^a,c,f  

^a Anticancer Center François Baclesse   (France)

^b Biochemistry Laboratory   (France)

^c University Hospital Center Caen   (France)

^d GUANGXI MEDICAL UNIVERSITY   (China)

^e FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^f CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Cisplatin; Energetic metabolism; Glycolysis; Mesothelioma; MSTO 211H

Indexed keywords

6 PHOSPHOFRUCTOKINASE; CISPLATIN; CITRIC ACID; HEXOKINASE; PROTEIN BCL XL; PROTEIN MCL 1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL KILLING; CELL PROLIFERATION; CYTOTOXICITY; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CELL LINE, TUMOR; CISPLATIN; CITRATES; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS;

EID: 64949128867     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Lund LG and Aust AE: Iron-catalyzed reactions may be responsible for the biochemical and biological effects of asbestos. Biofactors 3: 83-89, 1991.
2. Ribak J and Selikoff IJ: Survival of asbestos insulation workers with mesothelioma. Br J Ind Med 49: 732-735, 1992.
3. Peto J, Decarli A, La VC, Levi F and Negri E: The European mesothelioma epidemic. Br J Cancer 79: 666-672, 1999.
4. Warburg O: On the origin of cancer cells. Science 123: 309-314, 1956.
5. Ko YH, Pedersen PL and Geschwind JF: Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 173: 83-91, 2001.
6. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ and Huang P: Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug-resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 65: 613-621, 2005.
7. Geschwind JF, Ko YH, Torbenson MS, Magee C and Pedersen PL: Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 62: 3909- 3913, 2002.
8. Danial NN, Gramm CF, Scorrano L, Zhang CY, Krauss S, Ranger AM, Datta SR, Greenberg ME, Licklider LJ, Lowell BB, Gygi SP and Korsmeyer SJ: BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 424: 952-956, 2003.
9. Zhang XD, Deslandes E, Villedieu M, Poulain L, Duval M, Gauduchon P, Schwartz L and Icard P: Effect of 2-deoxy-D- glucose on various malignant cell lines in vitro. Anticancer Res 26: 3561-3566, 2006.
10. Stryer L: Biochemistry (3d ed). New York, W. H. Freeman and Company, 1988.
11. Leist M, Single B, Castoldi AF, Kuhnle S and Nicotera P: Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 185: 1481-1486, 1997.
12. Lieberthal W, Menza SA and Levine JS: Graded ATP depletion can cause necrosis or apoptosis of cultured mouse proximal tubular cells. Am J Physiol 274: F315-F327, 1998.
13. L down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells. Gynecol Oncol 105: 31-44, 2007.
14. Kindler HL: Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol 2-3: 171-179, 2008.
15. L antisense treatment. Int J Cancer 106: 160-166,2003.
16. O'Kane SL, Pound RJ, Campbell A, Chaudhuri N, Lind MJ and Cawkwell L: Expression of bcl-2 family members in malignant pleural mesothelioma. Acta Oncol 45: 449-453, 2006.
17. L, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19: 1294-1305, 2005.
18. Fennell DA and Rudd RM: Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. Lancet Oncol 5: 354-362, 2004.